Revenue ($USD) : $19,552,000,000
R&D spend : $1,205,000,000
Employees : 51,000
Fiscal year end : 12/31/2023
CEO : Peter Arduini

www.gehealthcare.com

GE HealthCare is facing headwinds in the market in China, which caused it in July to reduce its organic revenue growth projection to 1–2%, versus the previous projection of 4%. CEO Peter Arduini highlighted year-over-year sales growth and margin expansion in the second quarter: “We are pleased with our continued progress in advancing our margin goals, while continuing our investments for future growth.” GE HealthCare continues with new partnerships, products and tuck-in acquisitions, especially when it comes to medtech innovations enabled by artificial intelligence. Recent AI-related moves include:

• A joint development agreement with Volta Medical over AI-driven electrophysiology tech;


• Acquiring Intelligent Ultrasound Group’s clinical AI software business;


• The launch of the AI-enhanced Voluson Signature 20 and 18 ultrasound systems for women’s health imaging applications;


• A partnership with Biofourmis to use its FDA-cleared, AI-guided algorithms to help deliver personalized healthcare and health monitoring in people’s homes.

In addition, GE HealthCare in May announced the launch of its “new era” of AI-enhanced oncology solutions, known as Revolution RT. –CN